重度嗜酸性哮喘停用与持续长期美泊利单抗治疗的比较(COMET研究)
COMET研究为随机双盲安慰剂对照多中心试验,纳入已连续接受美泊利单抗≥3年的重度嗜酸性哮喘患者,按1:1随机分为停药组(换用安慰剂)与继续组(皮下美泊利单抗100 mg每4周一次,共52周)。结果显示停药组首次临床显著急性发作时间、哮喘控制下降时间均显著短于继续组,第52周血嗜酸性粒细胞计数显著更高。
要点
- 停用美泊利单抗后临床显著急性发作风险增加(HR 1.61)。
- 停药组哮喘控制下降风险更高(HR 1.52)。
- 停药后第52周血嗜酸性粒细胞计数显著高于继续组。
核心结论
- 停用美泊利单抗的重度嗜酸性哮喘患者较继续治疗者急性发作增加、哮喘控制下降。
研究设计与样本
- COMET(NCT02555371)为随机、双盲、安慰剂对照、平行组、多中心研究。
- 纳入完成COLUMBA或COSMEX研究且连续接受美泊利单抗治疗≥3年的患者,1:1随机分为停药组(n=151)与继续组(n=144),继续组皮下美泊利单抗100 mg每4周一次,共52周。
主要发现
- 停药组较继续组首次临床显著急性发作时间显著缩短(HR 1.61,95%CI 1.17-2.22;p=0.004)。
- 停药组较继续组哮喘控制下降时间显著缩短(HR 1.52,95%CI 1.13-2.02;p=0.005)。
- 第52周血嗜酸性粒细胞计数停药组270 cells·µL-1 vs 继续组40 cells·µL-1,比值6.19(95%CI 4.89-7.83;p<0.001)。
- 两组疗效差异自第12周(末次美泊利单抗给药后16周)评估时出现。
- 需住院/急诊就诊的急性发作罕见;继续组不良事件与既往研究一致,停药组安全性特征与其他嗜酸性哮喘人群一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The long-term efficacy and safety of mepolizumab for treatment of severe eosinophilic asthma are well established. Here, we examine the clinical impact of stopping mepolizumab after long-term use. METHODS: COMET (NCT02555371) was a randomised, double-blind, placebo-controlled, parallel-group, multicentre study. Patients who had completed COLUMBA (NCT01691859) or COSMEX (NCT02135692) and received continuous mepolizumab treatment for ≥3 years were randomised 1:1 to stop (switch to placebo) or continue subcutaneous mepolizumab 100 mg every 4 weeks for 52 weeks. Primary end-point: time to first clinically significant exacerbation; secondary end-points: time to first exacerbation requiring hospitalisation/emergency department visit, time to decrease in asthma control (≥0.5-point increase in Asthma Control Questionnaire-5 score from COMET baseline) and blood eosinophil count ratio to COMET baseline. Safety was assessed. RESULTS: Patients stopping (n=151) versus continuing (n=144) mepolizumab had significantly shorter times to first clinically significant exacerbation (hazard ratio 1.61, 95% CI 1.17-2.22; p=0.004) and decrease in asthma control (hazard ratio 1.52, 95% CI 1.13-2.02; p=0.005), and higher blood eosinophil counts at week 52 (270 versus 40 cells·µL-1; ratio (stopping versus continuing) 6.19, 95% CI 4.89-7.83; p<0.001). Differences in efficacy outcomes between groups were observed when assessed from week 12 (16 weeks after last mepolizumab dose). Exacerbations requiring hospitalisation/emergency department visit were rare. Adverse events in patients continuing mepolizumab were consistent with previous studies. For patients who stopped mepolizumab, the safety profile was consistent with other eosinophilic asthma populations. CONCLUSION: Patients who stopped mepolizumab had an increase in exacerbations and reduced asthma control versus those who continued.
引用
- Moore WC, Kornmann O, Humbert M, et al. Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study). Eur Respir J. 2022. PMID: 34172470. doi:10.1183/13993003.00396-2021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。